Evidence map›Paper›PMID 33851009›Full record

ArticleMolecular therapy oncolytics2021

Introducing a new reporter gene, membrane-anchored

Maxim A Moroz, Juan Zurita, Anna Moroz, Ekaterina Nikolov, Yury Likar, Konstantin Dobrenkov, Jason Lee, Larissa Shenker, Ronald Blasberg, Inna Serganova and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy oncolytics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Copper-mediated oxidation of imidazopyrazinones inhibits marine luciferase activity.Luminescence : the journal of biological and chemical luminescence · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Maxim A MorozDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Juan ZuritaDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Anna MorozDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ekaterina NikolovDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Yury LikarDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Konstantin DobrenkovDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jason LeeDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Larissa ShenkerDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ronald BlasbergDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Inna SerganovaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Vladimir PonomarevDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Memorial Sloan Kettering Cancer Center · USSkolkovo Institute of Science and Technology · RU

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Imaging tumor and T cell responses to metabolic and immune modulation therapyR01CA215136 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MERGHOUB, TAHA · 2017 to 2021
$3.8M
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell TherapyR01CA204924 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2016 to 2020
$3.5M
Image-guided TRAIL-enhanced CAR T-cell immunotherapyR01CA220524 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2018 to 2022
$2.9M
Imaging and Targeting Metastatic-Prone Breast CancerR01CA172846 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BLASBERG, RONALD GEORGE, KOUTCHER, JASON ARTHUR · 2013 to 2017
$2.8M
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survivalR01CA163980 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BLASBERG, RONALD GEORGE, PONOMAREV, VLADIMIR · 2012 to 2016
$2.5M
Exploiting tumor metabolism to optimize T cell therapyR50CA221810 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Inna Serganova · 2018 to 2026
$1.6M
Secretable theranostic payloads to augment the efficacy of adoptive CAR-T cell therapiesR21CA250478 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2020 to 2020
$455k
Imaging the efficacy of TRAIL-enhanced cancer immunotherapyR21CA213139 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., PONOMAREV, VLADIMIR · 2017 to 2018
$413k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA163980NCI NIH HHS R01 CA172846NCI NIH HHS R01 CA204924NCI NIH HHS R01 CA215136NCI NIH HHS R01 CA220524NCI NIH HHS R21 CA213139NCI NIH HHS R21 CA250478NCI NIH HHS R50 CA221810
6 · The paper itself

Abstract

Bioluminescence reporter gene imaging is a robust, high-throughput imaging modality that is useful for tracking cells and monitoring biological processes, both in cell culture and in small animals. We introduced and characterized a novel bioluminescence reporter-membrane-anchored

Indexed as

bioluminescence imagingBLIluciferase reportersmultiplex imagingreporter gene

Identifiers

PMID33851009
PMCPMC8020342
OpenAlexW3136826821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.